Compare ARMOUR Residential REIT, Inc. (ARR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs IDEXX Laboratories, Inc. — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.67 (market cap $2.07B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 22.3× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ARR | IDXX | |
|---|---|---|
Market Cap | $2.07B | $46.22B |
Sector | Financials | Health |
52-Week High | $19.12 | $766.68 |
52-Week Low | $14.05 | $526.44 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $16.67, up 0.79% today, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a net income margin of 97.43% and a low P/E of 3.78, but revenue volatility and high investing cash outflows pose concerns. Recent dividends of $0.24 per share highlight income appeal, while analyst consensus is predominantly hold.
Outlook is cautious due to inconsistent EPS performance and significant cash flow swings, though valuation metrics suggest potential undervaluation. Risks include earnings misses and macroeconomic sensitivity, but the high dividend yield and low P/B ratio offer value for income-focused investors amid neutral market sentiment.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
